Rimegepant comment watch save

  • FDA APPROVAL DATE: 02/27/2020
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    Fluconazole, Itraconazole, Rifampin, strong CYP3A4 inhibitors; moderate CYP3A4 inhibitors; strong and moderate CYP3A inducers; inhibitors of P-gp or BCRP
  • PREGNANCY: No adequate data on the developmental risk associated with use in pregnant women.

Please login to view the rest of this drug profile.

Page last updated 04/26/2024

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top